{"title":"多发性骨髓瘤患者控制营养状态评分的预后和临床病理价值：一项荟萃分析。","authors":"Yin Jin, Wenfei Gu","doi":"10.3389/fonc.2025.1517223","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The effect of the controlling nutritional status (CONUT) score on forecasting multiple myeloma (MM) prognosis is previously analyzed, whereas the results remained inconsistent. The present meta-analysis focused on identifying the exact function of CONUT in forecasting MM prognosis.</p><p><strong>Methods: </strong>Web of Science, PubMed, Embase, CNKI, and Cochrane Library were comprehensively searched between inception and 1 February 2025. The effect of CONUT on forecasting MM overall survival (OS) and progression-free survival (PFS) was determined by computing pooled hazard ratios (HRs) together with 95% confidence intervals (CIs).</p><p><strong>Results: </strong>There were nine studies with 1,176 patients being recruited into the present work. As indicated by our pooled data, elevated CONUT was related to the dismal OS (HR = 1.87, 95% CI = 1.37-2.54, <i>p</i> < 0.001) of patients with MM. Nonetheless, CONUT was not significantly related to PFS (HR = 1.33, 95% CI = 0.81-2.19, <i>p</i> = 0.254) of MM. Furthermore, higher CONUT score showed a significant relationship to bone marrow plasma cells >30% (OR = 2.30, 95% CI = 1.32-3.99, <i>p</i> = 0.003). On the other hand, CONUT was not markedly correlated with gender (OR = 2.68, 95% CI = 0.81-8.82, <i>p</i> = 0.105), ISS stage (OR = 1.28, 95% CI = 0.94-1.75, <i>p</i> = 0.119), or ECOG PS (OR = 1.30, 95% CI = 0.84-2.01, <i>p</i> = 0.234) of MM.</p><p><strong>Conclusion: </strong>Collectively, according to our results in this meta-analysis, higher CONUT score is markedly related to dismal OS, but not PFS in patients with MM. CONUT score can be used as a candidate marker used to predict MM prognosis in the clinic in the future.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1517223"},"PeriodicalIF":3.5000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959075/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis.\",\"authors\":\"Yin Jin, Wenfei Gu\",\"doi\":\"10.3389/fonc.2025.1517223\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The effect of the controlling nutritional status (CONUT) score on forecasting multiple myeloma (MM) prognosis is previously analyzed, whereas the results remained inconsistent. The present meta-analysis focused on identifying the exact function of CONUT in forecasting MM prognosis.</p><p><strong>Methods: </strong>Web of Science, PubMed, Embase, CNKI, and Cochrane Library were comprehensively searched between inception and 1 February 2025. The effect of CONUT on forecasting MM overall survival (OS) and progression-free survival (PFS) was determined by computing pooled hazard ratios (HRs) together with 95% confidence intervals (CIs).</p><p><strong>Results: </strong>There were nine studies with 1,176 patients being recruited into the present work. As indicated by our pooled data, elevated CONUT was related to the dismal OS (HR = 1.87, 95% CI = 1.37-2.54, <i>p</i> < 0.001) of patients with MM. Nonetheless, CONUT was not significantly related to PFS (HR = 1.33, 95% CI = 0.81-2.19, <i>p</i> = 0.254) of MM. Furthermore, higher CONUT score showed a significant relationship to bone marrow plasma cells >30% (OR = 2.30, 95% CI = 1.32-3.99, <i>p</i> = 0.003). On the other hand, CONUT was not markedly correlated with gender (OR = 2.68, 95% CI = 0.81-8.82, <i>p</i> = 0.105), ISS stage (OR = 1.28, 95% CI = 0.94-1.75, <i>p</i> = 0.119), or ECOG PS (OR = 1.30, 95% CI = 0.84-2.01, <i>p</i> = 0.234) of MM.</p><p><strong>Conclusion: </strong>Collectively, according to our results in this meta-analysis, higher CONUT score is markedly related to dismal OS, but not PFS in patients with MM. CONUT score can be used as a candidate marker used to predict MM prognosis in the clinic in the future.</p>\",\"PeriodicalId\":12482,\"journal\":{\"name\":\"Frontiers in Oncology\",\"volume\":\"15 \",\"pages\":\"1517223\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-03-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959075/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fonc.2025.1517223\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2025.1517223","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：以前曾分析过控制营养状况（CONUT）评分对预测多发性骨髓瘤（MM）预后的影响，但结果仍不一致。本荟萃分析的重点是确定CONUT在预测MM预后中的确切功能。方法：综合检索Web of Science、PubMed、Embase、CNKI、Cochrane Library，检索时间为建站至2025年2月1日。CONUT对预测MM总生存期（OS）和无进展生存期（PFS）的影响通过计算合并风险比（hr）和95%置信区间（ci）来确定。结果：本研究共纳入9项研究，1176例患者。我们的汇总数据显示，CONUT升高与MM患者的低OS （HR = 1.87, 95% CI = 1.37-2.54, p < 0.001）有关。然而，CONUT与MM的PFS （HR = 1.33, 95% CI = 0.81-2.19, p = 0.254）无显著相关性。此外，较高的CONUT评分与骨髓浆细胞bbb30 %有显著关系（OR = 2.30, 95% CI = 1.32-3.99, p = 0.003）。另一方面,CONUT与性别没有显著相关(OR = 2.68, 95% CI -8.82 = 0.81, p = 0.105), ISS阶段(OR = 1.28, 95% CI -1.75 = 0.94, p = 0.119),或ECOG PS (OR = 1.30, 95% CI -2.01 = 0.84, p = 0.234) MM.Conclusion:总的来说,根据我们的研究结果在这个荟萃分析,高CONUT得分显著相关惨淡的操作系统,但不是PFS MM患者。CONUT分数可以用作候选标记用来预测预后毫米在未来在诊所。
Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis.
Background: The effect of the controlling nutritional status (CONUT) score on forecasting multiple myeloma (MM) prognosis is previously analyzed, whereas the results remained inconsistent. The present meta-analysis focused on identifying the exact function of CONUT in forecasting MM prognosis.
Methods: Web of Science, PubMed, Embase, CNKI, and Cochrane Library were comprehensively searched between inception and 1 February 2025. The effect of CONUT on forecasting MM overall survival (OS) and progression-free survival (PFS) was determined by computing pooled hazard ratios (HRs) together with 95% confidence intervals (CIs).
Results: There were nine studies with 1,176 patients being recruited into the present work. As indicated by our pooled data, elevated CONUT was related to the dismal OS (HR = 1.87, 95% CI = 1.37-2.54, p < 0.001) of patients with MM. Nonetheless, CONUT was not significantly related to PFS (HR = 1.33, 95% CI = 0.81-2.19, p = 0.254) of MM. Furthermore, higher CONUT score showed a significant relationship to bone marrow plasma cells >30% (OR = 2.30, 95% CI = 1.32-3.99, p = 0.003). On the other hand, CONUT was not markedly correlated with gender (OR = 2.68, 95% CI = 0.81-8.82, p = 0.105), ISS stage (OR = 1.28, 95% CI = 0.94-1.75, p = 0.119), or ECOG PS (OR = 1.30, 95% CI = 0.84-2.01, p = 0.234) of MM.
Conclusion: Collectively, according to our results in this meta-analysis, higher CONUT score is markedly related to dismal OS, but not PFS in patients with MM. CONUT score can be used as a candidate marker used to predict MM prognosis in the clinic in the future.
期刊介绍：
Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
